Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 8/20 | 0.57 |
| ▸ | BRD4 | O60885 | 8/20 | 0.56 |
| ▸ | BRD2 | P25440 | 8/20 | 0.56 |
| ▸ | BRD3 | Q15059 | 8/20 | 0.56 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.56 |
| ▸ | CCKAR | P32238 | 4/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8682571 | 1.00 | CCKBR (0.57) | CCKBRBRD4BRD2BRD3SENP1 | |
| SCHEMBL8682574 | 1.00 | CCKBR (0.57) | CCKBRBRD4BRD2BRD3SENP1 | |
| SCHEMBL11961521 | 0.93 | BRD4 (0.55) | CCKBRBRD4BRD2BRD3SENP1 | |
| SCHEMBL9469880 | 0.89 | CCKBR (0.62) | CCKBRCCKAR | |
| SCHEMBL9525844 | 0.89 | CCKBR (0.62) | CCKBRCCKAR | |
| SCHEMBL11981798 | 0.89 | CCKBR (0.49) | CCKBRBRD4BRD2BRD3SENP1 | |
| SCHEMBL1574399 | 0.89 | CCKBR (0.65) | CCKBRSENP1CCKAR | |
| SCHEMBL641969 | 0.89 | CCKBR (0.65) | CCKBRSENP1CCKAR | |
| SCHEMBL8711252 | 0.89 | CCKBR (0.65) | CCKBRSENP1CCKAR | |
| Water SCHEMBL9229371 | 0.88 | CCKBR (0.64) | CCKBRSENP1CCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695179-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2016-01-28 | — | — | US | disclosed |
| EP-0730454-A4 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO INC (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-0907644-A4 | PHARMACEUTICAL PREPARATION | MERCK & CO INC (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-0907644-A1 | PHARMACEUTICAL PREPARATION | Merck & Co., Inc. (US) | 1999-04-14 | — | — | EP | disclosed |
| US-5834464-A | ANXIOLYTIC AGENTS, CHOLECYSTOKININ B ANTAGONISTS | MERCK & CO., INC. (US) | 1998-11-10 | — | — | US | disclosed |
| US-5817658-A | ADMINISTERING A DIAZEPINE COMPOUND; DISEASES OF THE EAR | MERCK & COMPANY, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5776930-A | CARDIOVASCULAR DISORDERS | MERCK & COMPANY, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1998000405-A1 | PHARMACEUTICAL PREPARATION | MERCK & CO., INC. (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1997049690-A1 | A METHOD FOR TREATING MENIERE'S DISEASE | MERCK & CO., INC. (US) | 1997-12-31 | — | — | WO | disclosed |
| US-5679672-A | ANITARRHYTHMIC AGENTS | MERCK & CO., INC. (US) | 1997-10-21 | — | — | US | disclosed |
| US-5595990-A | TREATMENT OF CARDIOVASCULAR DISORDERS | MERCK & CO., INC. (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0730454-A1 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO. INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5439906-A | Antiarrhythmic benzodiazepines | MERCK & CO., INC. (US) | 1995-08-08 | — | — | US | disclosed |
| US-5426185-A | Antiarrhythmia agents having reduced side effects | MERCK & CO., INC. (US) | 1995-06-20 | — | — | US | disclosed |
| WO-1995014471-A1 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| WO-1995014693-A1 | IMIDAZOLINOBENZODIAZEPINES | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| US-5185331-A | Administering to treat panic and anxiety disorders | MERCK & CO., INC. (US) | 1993-02-09 | — | — | US | disclosed |
| EP-0514125-A1 | Triazolobenzodiazepines | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, BRD3, BRDT | CCKBR 3917/4885BRD4 4/4885BRD2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.